246 related articles for article (PubMed ID: 31360084)
1. Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma.
Bhutani D; Zonder JA
Blood Lymphat Cancer; 2017; 7():53-60. PubMed ID: 31360084
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib for relapsed and refractory multiple myeloma.
Groen K; van de Donk N; Stege C; Zweegman S; Nijhof IS
Cancer Manag Res; 2019; 11():2663-2675. PubMed ID: 31037034
[TBL] [Abstract][Full Text] [Related]
4. Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
Nooka A; Gleason C; Casbourne D; Lonial S
Biologics; 2013; 7():13-32. PubMed ID: 23386784
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
6. A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.
Franken B; van de Donk NW; Cloos JC; Zweegman S; Lokhorst HM
Ther Adv Hematol; 2016 Dec; 7(6):330-344. PubMed ID: 27904737
[TBL] [Abstract][Full Text] [Related]
7. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma.
Jayaweera SPE; Wanigasinghe Kanakanamge SP; Rajalingam D; Silva GN
Front Oncol; 2021; 11():740796. PubMed ID: 34858819
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma.
Fostier K; De Becker A; Schots R
Onco Targets Ther; 2012; 5():237-44. PubMed ID: 23055749
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib boosted combination therapy for relapsed multiple myeloma.
Steiner RE; Manasanch EE
Onco Targets Ther; 2017; 10():895-907. PubMed ID: 28243125
[TBL] [Abstract][Full Text] [Related]
13. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
14. The role of carfilzomib in relapsed/refractory multiple myeloma.
Yee AJ
Ther Adv Hematol; 2021; 12():20406207211019612. PubMed ID: 34163580
[TBL] [Abstract][Full Text] [Related]
15. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Martin TG
Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
Stewart AK
Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.
Jain S; Diefenbach C; Zain J; O'Connor OA
Core Evid; 2011; 6():43-57. PubMed ID: 21654882
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Vandross A
Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
[TBL] [Abstract][Full Text] [Related]
20. An overview of the role of carfilzomib in the treatment of multiple myeloma.
Ziogas DC; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Pharmacother; 2017 Dec; 18(17):1883-1897. PubMed ID: 29134824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
